6 February 2013
Smiths Medical, a division of global technology business Smiths Group, has received a key clearance from the US Food and Drug Administration (FDA) to launch an advanced version of its portable infusion system designed specifically for home care.
The new CADD®-Solis VIP, which can now be marketed in the US, features advanced medication safety software that alerts operators or interrupts the infusion process when a pump setting is programmed outside preconfigured limits.
Srini Seshadri, President of Smiths Medical, said: “The CADD®-Solis VIP provides enhanced safety features and convenience for healthcare providers who want to provide optimal care for their infusion patients in the home. The FDA 510 (k) clearance allows it to be sold in our biggest single market by far.”
The CADD®-Solis VIP is used to administer pain relief medications, including narcotics, to post-surgery, trauma, cancer and labour patients. The patented software built into the system is also designed to recognise prescription errors, dose misinterpretations, and keypad programming mistakes. It is currently available in France, Germany, Switzerland, the Netherlands, Canada, Australia, the UK, and the Middle East.
General media enquiries
Contact our global media and communications team at:
Please note – the press team can only answer enquiries from accredited members of the press.
Related articles
Smiths Group plc – Q1 Trading Update
Find out more
Smiths Detection supplies industry-leading 3D X-ray scanners to Kansai International Airport
Passengers passing through Osaka’s busiest airport will soon be able to leave liquids and electronics in bags.
Find out more
Smiths Detection receives key certification for its AI-powered threat detection technology
AI-empowered technology identifies a wide range of airport threats and meets strict EU and Dutch requirements, setting an industry benchmark
Find out more
